Compare Kinder Morgan Inc (KMI) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinder Morgan Inc vs Mesoblast Limited — how do they compare? Kinder Morgan Inc trades at $32.49 (market cap $71.81B), while Mesoblast Limited trades at $14.24 (market cap $1.75B). The key difference: Kinder Morgan Inc is far larger — about 41× Mesoblast Limited's market cap, and Kinder Morgan Inc pays a 3.66% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kinder Morgan Inc for 150 Days and Mesoblast Limited for 15 Days on average.
| KMI | MESO | |
|---|---|---|
Market Cap | $71.81B | $1.75B |
Volume | 16,921,908 | 239,027 |
Sector | Energy | Health |
52-Week High | $34.31 | $20.96 |
52-Week Low | $25.84 | $13.19 |
Typical Hold Time | 150 Days | 15 Days |
Enterprise Value | $103.86B | $1.83B |
Dividend Yield | 3.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinder Morgan (KMI) trades at $32.49, up 2.11% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with revenue growth from $15.1B in 2024 to $16.94B in 2025 and net income margin expanding to 19.31%. Recent earnings beats and a $10B project backlog support growth prospects, while analyst consensus targets $37.20 with 47% buy ratings.
KMI presents a compelling investment case with stable fee-based revenues, dividend yield support, and natural gas infrastructure growth. Key risks include energy market volatility and high debt levels ($29.66B long-term). The stock offers upside potential from current levels but requires monitoring of cash flow sustainability and interest rate sensitivity.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
